文献速递口腔修复与种植

影响骨稳态的药物与种植体失败的关系

Effect of agents affecting bone homeostasis on short- and long-term implant failure.
PubMed 文献 · Clin Oral Implants Res · 2023-01-01

本综述检索了PubMed、MEDLINE、EMBASE、Cochrane图书馆和Web of Science等数据库,评估双膦酸盐、地舒单抗、甲氨蝶呤、糖皮质激素、罗莫索单抗、舒尼替尼和贝伐珠单抗与种植体失败的关系。现有证据不足以确立这些药物与种植体失败之间的潜在联系,但部分研究报告了种植治疗的负面结果,且抗骨吸收治疗患者即使成功骨结合后仍可出现种植体周围死骨。

要点

  • 双膦酸盐不损害种植体存留,但高剂量静脉双膦酸盐治疗后种植失败风险增加
  • 抗骨吸收治疗患者即使成功骨结合,仍可发生种植体相关死骨致晚期失败
  • 地舒单抗、甲氨蝶呤和糖皮质激素对种植体存留的作用尚无定论

核心结论

  • 目前证据不足以确立影响骨稳态的药物与种植体失败之间的潜在联系,但部分研究报告了种植治疗的负面结果。
  • 抗骨吸收治疗患者即使成功骨结合,仍可出现种植体相关死骨,需引起注意。

研究设计与样本

  • 综述类研究,通过PubMed、MEDLINE(OVID)、EMBASE(OVID)、Cochrane图书馆和Web of Science等数据库电子检索双膦酸盐、地舒单抗、甲氨蝶呤、糖皮质激素、罗莫索单抗、舒尼替尼和贝伐珠单抗相关文献,并辅以手工检索。

主要发现

  • 既往发表文献提示双膦酸盐不损害种植体存留。
  • 一项研究记录显示,种植修复后接受高剂量静脉双膦酸盐治疗的患者种植失败风险增加。
  • 抗骨吸收治疗前后成功接受种植治疗的患者可出现种植体周围MRONJ,导致晚期种植失败。
  • 地舒单抗、甲氨蝶呤和糖皮质激素对骨代谢有不利影响,但其在种植体存留中的作用尚无定论。

临床怎么用

  • 临床医生应仔细考虑影响骨稳态药物的潜在危害,并采取适当预防措施以降低药物与种植治疗相关风险。

局限性

  • 目前可用的研究有限,证据不足以确立影响骨稳态药物与种植体失败之间的潜在联系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review the current evidence on the relationship between agents that affect bone homeostasis and dental implant failures. MATERIALS AND METHODS: Electronic searches for bisphosphonates, denosumab, methotrexate, corticosteroids, romosozumab, sunitinib, and bevacizumab were performed using PubMed, MEDLINE (OVID), EMBASE (OVID), Cochrane Central Register of Controlled Trials (Cochrane Library), Cochrane Oral Health Group Trials Register (Cochrane Library) and Web of Science (Thomson Reuters). Manual searches were also conducted to complement the digital searches for recent issues. RESULTS: Previous publications suggested that bisphosphonates do not compromise the survival of dental implants. However, one study documented an increased risk of implant failure in patients who had received high-dose of intravenous bisphosphonate therapy after implant rehabilitation. There has been an issue of MRONJ around implants in patients who have successfully received implant therapy before and after antiresorptive therapy, leading to late implant failure. Despite evidence on the detrimental effects of denosumab, methotrexate and corticosteroids on bone metabolism, their role in implant survival is not conclusive. CONCLUSIONS: At present, there is insufficient evidence to establish a potential connection between agents that affects bone homeostasis and implant failure. However, some studies have reported negative results for implant therapy. In addition, implant-related sequestration in patients who received anti-resorptive therapy, despite of successful osseointegration, is also noticeable. Although limited studies are available at present, clinicians should still carefully consider the potential hazards and take appropriate precautions to minimize the risks associated with the medications and implant therapy.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Jung J, Ryu JI, Shim GJ, et al. Effect of agents affecting bone homeostasis on short- and long-term implant failure. Clin Oral Implants Res. 2023. PMID: 37750523. doi:10.1111/clr.14144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。